Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0005940 (
bone disease
)
7,459
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Appropriate imaging modalities for screening, staging, and surveillance of patients with suspected and documented metastatic disease to bone include (99m)Tc bone scanning, MRI, CT, radiography, and 2-[(18)F]fluoro-2-deoxyglucose-PET. Clinical scenarios reviewed include asymptomatic stage 1 breast carcinoma, symptomatic stage 2 breast carcinoma, abnormal bone scan results with breast carcinoma, pathologic fracture with known metastatic breast carcinoma, asymptomatic well-differentiated and poorly differentiated prostate carcinoma, vertebral fracture with history of malignancy, non-small-cell lung carcinoma staging, symptomatic multiple myeloma, osteosarcoma staging and surveillance, and suspected bone metastasis in a pregnant patient. No single imaging modality is consistently best for the assessment of metastatic
bone disease
across all tumor types and clinical situations. In some cases, no imaging is indicated. The recommendations contained herein are the result of evidence-based consensus by the
ACR
Appropriateness Criteria((R)) Expert Panel on Musculoskeletal Radiology.
...
PMID:ACR appropriateness criteria on metastatic bone disease. 2052 92
Chronic kidney disease (CKD) is efined as a reduction in estimated glomerular filtration rate (eGFR) for three consecutive months, or evidence of kidney damage alone with preserved renal function. CKD affects 8.5% of the UK population. Early recognition allows intervention that may delay or avoid progression to end-stage disease and modify the cardiovascular risk associated with CKD. CKD is classified into five stages and the majority of individuals have stages 1-3, many of these will never progress to end-stage renal disease. A decline in with age is expected. The most frequent specific renal diseases resulting in progressive CKD in the UK are: diabetes mellitus, atheromatous renal vascular disease, glomerulonephritis, chronic pyelonephritis and inherited renal disease. Laboratories in the UK now routinely provide an eGFR with a serum creatinine value in all adult patients. This estimation is based on serum creatinine, age, gender, and ethnicity. Baseline assessment in a patient with newly diagnosed CKD should include: blood pressure, dipstick urinalysis, urine
ACR
or PCR, glucose, lipid profile and a full blood count. Fluctuation in renal function is common, particularly in elderly patients with CKD. A fall in eGFR can result from any intercurrent illness, medication, or volume depletion. Proteinuria is a very important prognostic marker in CKD,
ACR
is the preferred measure as it has greater sensitivity for lower levels of proteinuria and is the recommended method in those with diabetes. The potential health problems associated with CKD can be divided into two main categories: risk of progressive renal disease with the development of renal
bone disease
and renal anaemia, and risk of overt cardiovascular disease.
...
PMID:Early recognition of CKD can delay progression. 2357 15